CANbridge Pharmaceuticals’ Maralixibat Approved by NMPA for Alagille Syndrome
China-based rare disease specialist CANbridge Pharmaceuticals Inc., (HKG: 1228) has announced receiving market approval from...
Boao Lecheng pilot zone
Antengene’s Xpovio Combination Therapy Approved for Reimbursement in Australia for R/R MM
China-based biotech Antengene Corp., Ltd (HKG: 6996) has revealed that Australia’s Pharmaceutical Benefits Scheme (PBS)...
Hainan Boao Lecheng Introduces 319 Overseas Drugs and Devices, Reports Significant Growth
The Hainan Boao Lecheng International Medical Tourism Pilot Zone has introduced 319 clinically urgently needed...
Hainan Province and NHSA Partner to Enhance Medical Insurance Industry with Real-World Data
The government of Hainan province has entered into a strategic partnership with the National Healthcare...
Enhertu, HER2-Targeted ADC, Officially Launched in China for Breast Cancer Treatment
Enhertu (trastuzumab deruxtecan), a HER2-targeted antibody-drug conjugate (ADC) co-developed by AstraZeneca (AZ, NASDAQ: AZN) and...
Antengene Submits Market Approval Filing for Xpovio in Indonesia for Multiple Myeloma and Lymphoma
Antengene Corp., Ltd (HKG: 6996) has announced a market approval filing in Indonesia for its...
Meihua International Medical Expands with New Healthcare Industrial Park in Hainan
Meihua International Medical Technologies Co., Ltd (NASDAQ: MHUA), has announced the acquisition of a land...
Everest Medicines’ Nefecon for IgAN Approved for Clinical Use in Hainan
China-based Everest Medicines (HKG: 1952) has announced that Nefecon (delayed-release budesonide), the first-in-disease treatment for...
EOC Pharma Group Partners with China National Accord Medicines for Distribution Rights
China-based EOC Pharma Group has announced a strategic partnership with compatriot firm China National Accord...
Hainan’s Boao Lecheng Partners with Sonova to Advance Hearing Health Solutions in China
The Boao Lecheng Medical Tourism Pilot Zone of Hainan Province has struck a strategic partnership...
Hainan Introduces Management Regulations for Urgently Needed Import Drugs and Devices in Boao Lecheng
The Hainan provincial government has issued a Notice on the Management Regulations for Clinically Urgently...
AffaMed Therapeutics Gets NMPA Approval for Phase III Dextenza Study in Post-Ophthalmic Surgery
China-based AffaMed Therapeutics has announced that it has received approval from the National Medical Products...
Junshi Biosciences’ JS401 Receives NMPA Approval for Hyperlipidemia Clinical Trial
Junshi Biosciences (HKG: 1877, SHA: 688180), a leading China-based biopharmaceutical company, has announced that it...
CStone Pharmaceuticals Reduces Ayvakit Price to Boost Accessibility in China
China-based CStone Pharmaceuticals (HKG: 2616) has announced a lower recommended price for its precision medicine...
Corxel Pharmaceuticals’ OC-01 Nasal Spray Approved as Urgently Needed Drug in Hainan
Shanghai-based Corxel Pharmaceuticals (CORXEL), supported by RTW Investments, has announced that its OC-01 (varenicline) nasal...
Boao Lecheng Medical Tourism Zone Partners with Eye Valley to Advance Ophthalmology Innovation
The Boao Lecheng Medical Tourism Pilot Zone in Hainan Province has announced a strategic partnership...
Kangtai Bio Partners with AstraZeneca and Combiphar to Expand Vaccine Collaboration
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a leading Chinese vaccine manufacturer, has entered...
Boao Lecheng and Shanghai Biomed Center Form Long-Term Partnership for Medical Innovation
The Boao Lecheng Medical Tourism Pilot Zone of Hainan Province has entered into a long-term...
Boston Scientific Launches REPLACE Study for FARAPULSE PFA System in China
US-based medical technology major Boston Scientific Corporation (NYSE: BSX) has announced the initiation of the...
Inmagene’s Tavalisse First Prescribed in China for ITP Treatment
China-based Inmagene Biopharmaceuticals has announced that its in-licensed drug Tavalisse (fostamatinib) has been first prescribed...